MedTrace Logo

Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases

NCT03910361 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2021-04-29

No results posted yet for this study

Summary

A multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver diseases

Conditions

  • Type2 Diabetes
  • Non-Alcoholic Fatty Liver Disease

Interventions

DRUG

Evogliptin

evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd

DRUG

Pioglitazone

pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Byung Wan Lee · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-12
Primary Completion
2020-07-02
Completion
2020-07-02

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03910361 on ClinicalTrials.gov